OBJECTIVE: Obesity poses a serious health hazard and its treatment is often disappointing. This review describes the present status of pharmacological treatment of obesity in man. DESIGN: Obesity treatment may include drugs that reduce food intake, drugs that increase energy expenditure and drugs that affect nutrient partitioning or metabolism. The mode of action, ef®cacy and safety of each approach will be brie¯y discussed. RESULTS: All of the pharmacological possibilities have potential activities, but also serious limitations. While current anti-obesity pharmacotherapy essentially uses centrally-acting anorectic drugs, severe side-effects (more particularly pulmonary hypertension and valvular heart disease) have been reported, leading to the withdrawal of licensed fen¯uramine and d-fen¯uramine. New approaches have been recently proposed, such as sibutramine, an amine reuptake inhibitor which decreases food intake, and orlistat, an intestinal lipase inhibitor which decreases fat absorption.
Introduction
Obesity prevention and management should be given as much priority and skill by all professionals as it would be given to any other common chronic disease with such serious consequences. 1, 2 The basis of obesity management is very simple but the expectations are usually unrealistic 3 and the treatment using conservative methods (low-calorie diet and regular physical exercise) remains a largely unachieved goal. 1 Several pharmacological approaches have been proposed to promote weight loss andaor minimize weight regain (review in refs. 4 ± 7 ) and the need for and logic of anti-obesity drug treatment have been recognized. 8 While the pharmacological market of anti-obesity drugs remained almost unchanged for several decades, the last year has been characterized by two major events: ®rst, the withdrawal, because of reported serious side effects, of two drugs widely used in Europe and in the US (fen¯uramine and dexfen¯ur-amine); and second, the ®nal clinical development of two promising new compounds with different modes of action (sibutramine and orlistat).
Considering the controlled system regulating body weight, three different mechanisms may be used to classify pharmacological treatments of obesity: (1) drugs that reduce food intake; (2) drugs that increase energy expenditure; and (3) drugs that affect metabolism or nutrient partitioning. 1,4,5 ± 7 Although the pharmacological approach for the last decades was mainly based on the use of centrally-acting appetite-suppressing agents, 9 various drugs are under development which open new perspectives for the treatment of obesity.
Drugs that reduce food intake
By diminishing appetite, anorectic drugs result in a reduction of food intake which over time leads to a loss in body weight and fat mass. Anorectic drugs can play a useful role in an overall weight reduction programme, and should only be prescribed as part of such a programme. 9 
Noradrenergic drugs
All of the currently available appetite-suppressing drugs, except mazindol, are derivatives of phenylethyl-amine (amphetamine, phenmetrazine, amfepramone or diethylpropion, phentermine, phenylpropanolamine). Noradrenergic drugs release norepinephrine or block its reuptake into neurons of the hypothalamus. The only exception is phenylpropanolamine which acts as an alpha-1 adrenergic agonist. 4 ± 7,9 Among the catecholaminergic anorectics, amphetamine and phenmetrazine are no longer recommended because of their strong stimulatory properties and addictive potential. Amfepramone (diethylpropion), phentermine, phenylpropanolamine, and mazindol have reduced stimulant action but preserved anorectic effects. Side effects of a sympathomimetic nature may occur in some subjects. These drugs should be used with care because of the danger of psychological dependence and drug abuse, although most obese people do not experience this dif®culty. Recently, more serious side effects such as pulmonary hypertension 10 and valve heart disease 11 have been described, but most cases were observed when these noradrenergic drugs (essentially phentermine) were prescribed together with fen¯uramine (see below). Interestingly, intermittent treatment is as good and cheaper than continuous treatment with such catecholaminemediated drugs. 9 
Serotoninergic drugs
Fen¯uramine and dexfen¯uramine. Fen¯uramine and dexfen¯uramine are metabolized in the liver to d-norfen¯uramine which enhances serotonin release from the neurons and acts as an agonist for 5-HT 2C receptors. In addition, d-fen¯uramine acts to block reuptake of serotonin into the neurons. These processes concur in decreasing food intake. 4 ± 7,9 The clinical ef®cacy of fen¯uramine (60 mgad) and dexfen¯uramine (2 Â 15 mgad) has been demonstrated in trials of short and long duration conducted over the past 30 years and was almost similar to that reported with noradrenergic agents. 12, 13 In contrast to catecholaminergic drugs, serotoninergic compounds should be used continuously and do not exert stimulant or sympathomimetic activities nor induce tolerance. However, although it was generally considered that these compounds have a wide margin of safety, several reports of pulmonary hypertension 10 and, more recently, of cardiac valvular abnormalities, 11 have been published. Despite the fact that only very few cases of valvular heart disease have been described with the use of these serotoninergic drugs alone, these dramatic observations led the Servier company to withdraw, by caution, both fen¯uramine and dexfen¯uramine from the world market. It still remains unclear, however, whether treatment with fen¯uramine or dexfen¯uramine alone signi®cantly increases the incidence of valvular heart disease, the serious side effect reported late August 1997 11 which led to the rapid withdrawal of both specialties in midSeptember 1997.
Fluoxetine. Fluoxetine is a well-known antidepressant drug which acts by inhibiting the reuptake of serotonin into presynaptic neurons and which also exerts anorectic activity.
14 It is worth of noting that, in contrast to fen¯uramine,¯uoxetine does not stimulate serotonin release. This characteristic may explain why no cases of pulmonary hypertension or of cardiac valvular abnormalities have been described with this compound despite a very wide utilization as an antidepressant drug. That¯uoxetine is an effective anorectic agent promoting weight loss has been con®rmed in the obese subject, even in the absence of depression. 15 However, the dose effective to reduce body weight is higher (60 mgad) than that generally used in the role of anti-depressant drug (20 mgad) and the effect may be transient as a signi®cant weight regain has been reported between 6 and 12 months after starting chronic treatment. 15 Drugs affecting both norepinephrine and serotonin Drug combinations. As both norepinephrine and serotonin affect food behaviour, and as drugs acting on either norepinephrine or serotonin are available, the temptation was high to combine such compounds (especially phentermine fen¯uramine in the US and amfepramone fen¯uramine in some European countries such as Belgium) in order to improve the ef®cacy on weight loss or to minimize side effects by reducing the dosage of each anorectic agent. 16 The combination of phentermine and fen¯uramine has attracted considerable medical and media attention in the US since the publication of a long-term trial which suggested the ef®cacy and safety of such a combination, 17 and these results were con®rmed in another large study. 16 However, the recent publication pointing out the risk of severe valvular cardiac abnormalities with the combination phentermine ± fen¯uramine, 11 associated with the potential risk of pulmonary hypertension, 10 has recently thrown discredit on such a combined therapy.
Sibutramine. Sibutramine is a beta-phenethylamine, initially developed as antidepressant agent, with an interesting pharmacological pro®le. It inhibits the reuptake of both norepinephrine and serotonin at nerve endings, making it functionally similar to a combination of a noradrenergic drug and a serotoninergic drug. 18, 19 Devoid of anti-depressant activity, it decreases food intake through b 1 and 5HT 2Aa2C receptor agonist activity. In contrast to the association fen¯uramine ± phentermine, sibutramine does not stimulate norepinephrine or serotonin release so that the risk of pulmonary hypertension or of cardiac valvular abnormalities is probably negligible with this new compound. Sibutramine demonstrated a clear dosedependent effect on body weight in obese subjects receiving advice on diet and lifestyle changes, with Anti-obesity drugs AJ Scheen and PJ Lefe Âbvre doses of 10, 15, 20 and 30 mg being signi®cantly more effective than placebo. 20 These studies suggested that sibutramine may be a valuable drug for treatment of obesity, at a recommended dosage of 10 ± 15 mgad. The noradrenergic effects of the drug may cause a mild increase in heart rate and blood pressure in some individuals, or prevent the expected fall in these parameters with weight loss. The clinical importance of these adverse effects has not been established yet. 19 
Drugs that increase energy expenditure
While impaired thermogenesis is an important contributor to excessive lipid deposition in genetic and diet-induced obese rodents, the extent of impaired thermogenic responsiveness in human obesity is less clear. Nevertheless, the pharmacological stimulation of thermogenesis appears to be a rational target for anti-obesity action. 21 Thyroid hormones which stimulate metabolism and energy expenditure should not be used to treat obesity per se because they promote lean mass loss and have unacceptable side effects. Much interest has been aroused concerning the therapeutic potential of enhancing energy expenditure since the discovery of new atypical b 3 adrenoceptors. 22, 23 Classical anorectic drugs Some of the commonly prescribed catecholaminergic anorectic drugs also increase sympathetic activity and, in rodents, much of their anti-obesity activity appears to result in fact from the stimulation of thermogenesis in brown adipose tissue and skeletal muscle. However, there is no clear evidence that these drugs raise metabolic rate in man at the doses usually tolerated in clinical practice (review in ref 24) . Similarly, the effects of serotoninergic agents on energy expenditure in humans are probably small and, up to present, controverted. 24 Sibutramine is thought to enhance metabolic rate through stimulation of peripheral b 3 -adrenergic receptors but this effect remains to be more carefully investigated. 18, 19 Ephedrine ± caffeine Ephedrine, a synthetic adrenergic drug, stimulates norepinephrine secretion, which binds to a variety of alpha-and beta-receptors. 25 Ephedrine increases metabolic rate, probably by stimulating beta-3 adrenergic receptors 26 and enhances weight loss in a dosedependent manner. 25 The disadvantages of high-dose ephedrine (150 mgad) are that, acutely, arterial pressure rises, glycaemic control deteriorates and tremor is a problem. Therefore, to enhance the weight reducing properties of lower-dose ephedrine (60 mgad), caffeine, which delays norepinephrine degradation, has been proposed to be added. 25 The clinical ef®cacy and safety of the ephedrine ± caffeine combination as thermogenic and anti-obesity agent have been reviewed extensively.
21,25
Beta-3 adrenergic agonists
The discovery of a third b-adrenergic receptor, the atypical or b 3 -adrenoceptor, and the demonstration that, in rodents, drugs targeted to this receptor prevent or correct obesity (and unexpectedly hyperglycaemia as well) have intensi®ed the search for an anti-obesity drug that could safely augment thermogenesis and thus increase energy expenditure (review in refs 22,23). Unfortunately, the dramatic effect of b 3 agonists in rodents was not con®rmed in humans, probably because of the much smaller amount of such atypical receptors in the adipose tissue of the latter species. 27, 28 Nevertheless, some observations support the idea that a selective b 3 -adrenoceptor agonist could induce the appearance of thermogenically active brown adipose tissue in human adults. 23 Whatsoever, the role of b 3 -receptor in human obesity remains unclear 29 and further studies are still needed to assess the potential clinical ef®cacy of b 3 -adrenoceptor agonists in human obesity and type 2 diabetes. 23 
Drugs that affect nutrient partitioning
Because the digestibility of food and its metabolism are related to the control of food intake, it is not surprising that approaches which alter these factors have been selected for development of new medications for the treatment of obesity. 4, 5 Preabsorptive phase: inhibitors of gastric emptying
The limited effectiveness and side effects of the centrally acting anorectics have encouraged the search for appetite suppressants that function at peripheral sites. A promising area for potential therapeutic intervention is gastric emptying. Medications which inhibit gastric emptying may increase satiety directly and via intestinal hormones. New compounds, such as amylin derivatives (triproamylin or pramlintide) or glucagon-like peptide-1 (GLP-1), decrease gastric emptying. Their ef®cacy has been studied in diabetic patients 30 but their potential effects on eating behaviour and body weight in man have not been established yet.
Absorptive phase: inhibitors of nutrient digestion
A direct approach to reduce caloric absorption by digestive means consists of regulating the action of the intestinal digestive enzymes.
Anti-obesity drugs AJ Scheen and PJ Lefe Âbvre Alpha-glucosidase inhibitors, such as acarbose (miglitol and voglibose are two other compounds), exert interesting antidiabetic activity (review in ref 31). They do not result in signi®cant weight reduction at usual doses tolerated by man, even if some prevention of weight regain has been reported after dietinduced weight loss in markedly obese individuals receiving very high doses of acarbose. 32 Agents that inhibit fat absorption or digestion are of theoretical bene®t in the treatment of obesity. Tetrahydrolipstatin (orlistat), an inhibitor of gastro-pancreatico-intestinal lipases, has been shown to reduce body mass whilst lowering blood lipid levels in both animals and humans. 33 Reduction of body weight results from a dose-dependent increased faecal fat excretion (up to 50 gad) 34 and probably also from a decreased dietary fat intake. Orlistat may indeed enforce behaviour change to avoid unpleasant intestinal side effects (liquid stools, faecal urgency and oil discharge). A short-term (12 weeks) study in obese patients showed that together with a low fat diet, orlistat produced a dose-dependent decrease in body weight, with a near maximal effect at a dose of 120 mg thrice daily. 35 Several multicentre placebo-controlled long-term (up to one year) clinical studies with such a daily dose have been performed in the US and in Europe and con®rmed the ef®cacy of the intestinal lipase inhibitor to promote weight loss (see below).
Postabsorptive phase: modulators of metabolism
While the use of thyroid hormones is no longer recommended in the treatment of obesity, the potential ef®cacy of other hormonal therapies has been evaluated more recently. 4, 5 Treatment with growth hormone has been reported to increase the amount of lean (muscular) tissue and decrease the amount of fat in hypopituitary human subjects, elderly people and obese subjects. Testosterone administration has been shown to signi®cantly decrease visceral fat and improve metabolic abnormalities associated with insulin resistance in hypoandrogenic obese men. Nevertheless, these hormonal approaches remain to be evaluated on a long-term basis and are not recommended in clinical practice yet. 4, 5 Modulation of fat storage and breakdown offers the possibility of modifying nutrient¯ux. Several approaches are currently tested in various animal models, but none has reached the level of clinical trials. The biguanide compound metformin, which is largely used in the obese diabetic patient, 36 might be included in this category, 4 ,5 since one of its mechanisms of action is through channeling peripheral glucose utilization.
Comparison of long-term studies regarding weight loss
In clinical practice, the effectiveness of an anti-obesity drug is essentially measured in terms of weight loss. 37 The Food and Drug Administration has provided one of the largest reviews of short-term (several weeks or months) effectiveness for anorectic drugs. It analysed 105 new drug applications containing data on 4543 placebo-treated and 3182 patients treated with active drugs. Drug-treated patients lost, on average, 0.23 kgaweek more than subjects receiving placebo, and no differences were observed between the various agents. 38 The results obtained during shortterm trials with serotoninergic drugs were similar to those reported with catecholaminergic compounds, that is, a mean weight loss of 0.25 kgaweek compared to placebo. 4 ± 7,9 Obesity is a chronic disease and should be treated as such. Consequently, only long-term effects of antiobesity drugs are of interest. 39 Unfortunately, before the last ten years, all clinical trials evaluating antiobesity drugs were limited to several weeks and many were not placebo-controlled. Table 1 summarizes the results reported with placebo-controlled one-year clinical trials involving various anti-obesity drugs, such as dexfen¯uramine,¯uoxetine, diethylpropion, sibutramine and orlistat. 40 ± 50 In the dexfen¯uramine studies, Results correspond to weight reductions measured in completers only, except in the three studies of orlistat (intention to treat analysis) ( a : P`0.05 between verum and placebo). 42 or group therapy 43 were used in both active and placebo groups. The number of patients included varied from about 20 in both experimental conditions to several hundreds. The percentage of drop-outs ranged between 20 and 50%. Interestingly, these percentages were generally lower in the groups treated by dexfen¯uramine, diethylpropion and orlistat when compared to placebo, while this was apparently not the case for¯uoxetine or sibutramine. Except for¯uoxetine, studies which included a suf®-ciently high number of patients ( b 100) demonstrated a signi®cantly greater weight loss with the active drug than with placebo. However, the mean difference was rather low, ranging between 2 and 4 kg after one year. The ef®cacy on weight loss can be evaluated in another way, by comparing the percentage of patients who achieved a reduction of at least 10% of initial body weight at 12 months ( Table 2) . Because of the rather high number of drop-outs in such long-term studies involving obese subjects, the analysis should be better performed on an intention-to-treat basis rather than on completers only. The results were remarkably concordant with the three drugs (dexfenuramine, sibutramine and orlistat) and the number of patients who reached this target was increased by a factor of about two to three with the active drug when compared to placebo, the differences being highly signi®cant with each compound.
Anti-obesity drugs
AJ Scheen and PJ Lefe Âbvre dietary advice for restricted diet, 40,41 low-calorie formula diet,
Practical guidelines for the use of anti-obesity drugs
Drug treatments for obesity may have detrimental effects of their own but the health risks of obesity itself should not be neglected. 37 The main characteristics of an ideal weight loss drug are the following: (1) orally active; (2) few or no side effects; (3) dosedependent reduction in body fat; (4) visceral fat decrease; (5) inexpensive; (6) long-acting; and (7) non-toxic. 37 Even if the mean weight loss achieved by prescribing an anti-obesity drug, whatever its type, is rather modest when compared to placebo in long-term trials involving large cohorts of obese patients (Table 1) , a growing body of information suggests that a loss of 5 to 10 % of initial body weight (Table 2) will provide signi®cant bene®t. So, a goal of`ideal body weight', or even`desirable body weight', is probably inappropriate for most overweight individuals. 37 Furthermore, individual responses to pharmacological approaches may be highly heterogenous, as`good responders' and`bad responders' have been described in most clinical studies. Perhaps the most important task in the future would be to select the right drug for the right patient. Obesity has many causes but the nature of these causes usually does not allow a de®nitive cure so that palliation and chronic treatment are the realistic therapeutic goals.
Practical guidelines for the pharmacological treatment of obesity can be summarized as follows: (1) use of pharmacological agents for long-term treatment of obesity should be considered for people with BMI ! 30 kgam 2 ; (2) failure to lose b 2 kg after 4 ± 8 weeks of treatment should be considered a treatment failure; (3) failure should lead to stopping initial monotherapy and to consider a new monotherapy or perhaps a drug combination; (3) the occurrence of a plateau in body weight after several months of treatment does not necessarily mean that the drug is becoming ineffective; (4) a realistic goal should be ®xed and the drug should be considered as effective if it induces and maintains a loss of 5 to 10 % of baseline body weight; (5) the treatment should be continued if the bene®ts outweigh the risks.
± 8
Anti-obesity drugs with positive effects on other risk factors Most available compounds proposed for treating obesity only induce a rather modest weight loss in most obese individuals. To justify long-term treatment, the coexistence of favourable effects on other risk factors would be welcome. Some anti-obesity drugs may indeed exert antidiabetic, antihypertensive andaor hypolipidaemic pharmacological activities, independently of weight reduction. The biguanide compound metformin 36 and the alphaglucosidase inhibitor acarbose 31 improve glucose control without inducing weight gain (or even promoting some weight loss). Their value for treating the obese patient with type 2 diabetes mellitus is well recognized. 24 Anti-obesity compounds might also exert bene®cial effect on glucose metabolism of the obese subject with or without overt diabetes. 24, 51, 52 All or the major part of the reducing effect on blood glucose may result from weight loss itself but some compounds appear to exert antihyperglycaemic activity per se, independently of weight reduction. This favourable action may result from a direct effect on insulin sensitivity as demonstrated for serotoninergic compounds such as dexfen¯uramine. 53 Whether sibutramine also exerts a direct favourable effect on insulin sensitivity remains to be proven in careful studies. 51, 52 Finally, a large multicentre one-year placebo-controlled study in obese individuals with type 2 diabetes demonstrated a better glucose control in patients receiving orlistat. 54 It remains to be determined whether such a long-term improvement in glycaemic control was only due to weight loss (even if rather modest) or resulted from another more speci®c effect.
Drugs with antihypertensive effect
Besides its well-known inhibitory effect on food intake 12 dexfen¯uramine has been shown to reduce arterial blood pressure. This effect may be mediated by a decrease in noradrenergic activity. 55, 56 In contrast, it should be noticed that the new compound sibutramine may slightly increase heart rate and arterial blood pressure. 19 The clinical signi®cance of such relatively small effects remains unclear.
Drugs with hypolipidaemic effect
Antidiabetic agents such as acarbose 31 and metformin 36 which are widely used in obese patients with type 2 diabetes could exert some favourable effects on lipid pro®le, essentially by decreasing serum triglyceride levels and sometimes by increasing HDL cholesterol concentrations. The selective inhibitor of gastric and pancreatic lipases, tetrahydrolipstatin (orlistat), has been shown to signi®cantly decrease serum total and LDL cholesterol levels in obese non diabetic individuals, 33, 34 in obese patients with type 2 diabetes 54 and in subjects with primary hyperlipidaemia. 57 
Conclusions
Obesity poses a serious health hazard. Obese patients need all the help they can get in the dif®cult task of losing weight and maintaining a lower body weight. Treatments for overweight Ð like those for most chronic illnesses Ð are palliative, not curative. The principles of treating obesity with drugs do not differ from any other disease. Drugs must be shown to be safe and effective with a high bene®t to risk ratio. They should also be part of an overall management strategy including food restriction and exercise. Weight loss generally obtained with monotherapy is rather modest, even after a prolonged treatment of up to one year. Pharmacological treatment of obesity, depending on severity, may necessitate intervention at several sites simultaneously to circumvent the multiple compensatory systems, which are working to maintain an elevated body fat content in the overweight patient. However, such a combined therapy, which is common in other chronic disease like arterial hypertension and type 2 diabetes mellitus, remains to be carefully evaluated in obesity. The recent better knowledge of the complex systems regulating body weight stimulates active research of new pharmacological compounds (more particularly peptides) for the treatment of the obese patient.
